Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...

Approximately every nine minutes, someone in the United States dies from a blood cancer, according to the Leukemia & Lymphoma ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow ... or kidney failure wasn’t associated with a worsened survival rate. Researchers concluded that the development of ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...